Article ID Journal Published Year Pages File Type
5824714 Clinical Therapeutics 2015 10 Pages PDF
Abstract
In this child and adolescent population, exposure parameters for lurasidone and its active metabolites were dose proportional in the range of 20 to 160 mg/d after the administration of single and multiple doses. These results suggest that lurasidone doses <120 mg/d were better tolerated compared with higher doses, especially in younger children. ClinicalTrials.gov identifier: NCT01620060.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, , , , , , , , ,